(0.04%) 5 471.66 points
(0.08%) 39 144 points
(0.35%) 17 779 points
(-0.07%) $80.77
(-3.66%) $2.66
(-0.77%) $2 312.90
(0.25%) $28.94
(3.59%) $1 021.80
(0.29%) $0.936
(0.68%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders...
Stats | |
---|---|
今日成交量 | 629 030 |
平均成交量 | 713 030 |
市值 | 3.43M |
EPS | $-1.188 ( Q2 | 2021-08-16 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.845 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0530 (1.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-09-09 | Coelho Mary Theresa | Buy | 10 310 | Stock option (right to buy) |
2021-08-11 | Coelho Mary Theresa | Buy | 0 | |
2021-07-09 | Pennington James | Buy | 100 000 | Stock option (right to buy) |
2021-06-30 | Schneiderman Daniel H | Buy | 250 000 | Stock option (right to buy) |
2021-06-30 | Schneiderman Daniel H | Buy | 35 006 | Stock option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 81 transactions |
Buy: 5 836 949 | Sell: 2 173 162 |
音量 相关性
AzurRx BioPharma Inc 相关性 - 货币/商品
AzurRx BioPharma Inc 财务报表
Annual | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-5 902 903 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-5 902 903 |
FY | 2019 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-6.77 |
FY | 2018 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-8.77 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AzurRx BioPharma Inc
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。